Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2001, for Bristol-Myers Squibb Company. The company is a global pharmaceutical and consumer health products firm. The reporting period includes significant corporate actions, specifically the planned divestiture of its Clairol beauty care business and the spin-off of its Zimmer orthopaedic business, which are classified as discontinued operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Net Sales | $9,398 million | $8,869 million |
| Net Earnings | $2,537 million | $2,312 million |
| Diluted EPS | $1.29 | $1.15 |
| Operating Cash Flow | $2,383 million | $1,584 million |
| Cash and Equivalents | $2,944 million | $2,222 million |
| Long-Term Debt | $1,302 million | $1,336 million |
| Working Capital | $4,258 million | $4,192 million |
Note: Working capital calculated as Total Current Assets ($9,519M) minus Total Current Liabilities ($5,261M).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% year-over-year (8% excluding foreign exchange), driven by a 6% volume increase and 2% price increase, partially offset by a 2% foreign exchange headwind.
- Profitability: Net earnings rose 10% to $2,537 million. Earnings from continuing operations increased 10% to $2,345 million.
- Product Mix Impact: Sales of key products GLUCOPHAGE (diabetes) and PLAVIX (cardiovascular) grew significantly (45% and 45% respectively for the six months). Conversely, sales of TAXOL (oncology) and BUSPAR (anxiety) declined due to generic competition.
- Expense Management: Total expenses as a percentage of sales improved to 66.1% from 67.4% in the prior year, aided by a 9% reduction in advertising and promotion expenditures.
- Divestitures: The company recorded a $77 million pretax gain on the sale of Estrace tablets and Apothecon commodity business. The Clairol business was sold to Procter & Gamble for $4.95 billion, and Zimmer was spun off to shareholders.
Guidance, Outlook, and Risks
- Acquisition: In June 2001, the company announced a definitive agreement to acquire DuPont Pharmaceuticals for $7.8 billion. To finance this, the company filed a registration statement to issue up to $5 billion in securities.
- Capital Allocation: The company increased its stock repurchase authorization by $2 billion to $14 billion. During the first six months of 2001, it repurchased 22 million shares for $1.3 billion.
- Legal Proceedings: Significant litigation surrounds TAXOL and BUSPAR patents. Courts have invalidated most TAXOL patent claims, leading to generic competition. The company faces antitrust investigations and lawsuits regarding the listing of the BUSPAR patent in the FDA Orange Book. Management states it is not possible to reasonably estimate the financial impact of these proceedings.
- Accounting Changes: The company adopted SFAS 133 regarding derivative instruments, which had no material effect. Future adoption of SFAS 141 and 142 regarding goodwill and business combinations is expected to have no material effect.
Investor Verification Checklist
- Verify the closing status and financing terms of the $7.8 billion DuPont Pharmaceuticals acquisition.
- Monitor the outcome of TAXOL and BUSPAR patent litigation, as generic competition continues to erode sales of these legacy products.
- Confirm the finalization of the Clairol sale to Procter & Gamble and the tax-free spin-off of Zimmer.
- Assess the impact of the increased R&D spending (up 12% year-over-year) on future pipeline development.
- Review the company's cash flow sustainability given the $1.3 billion in stock buybacks and upcoming acquisition costs.